



Extended mesenteric resection reduces the rate of surgical recurrence in Crohn's disease: a systematic review and meta-analysis

Sascha Vaghiri¹ · Ali Alipouriani² · Wolfram Trudo Knoefel¹ · Hermann Kessler² · Dimitrios Prassas^{1,3}

Accepted: 18 February 2025
© The Author(s) 2025

Abstract

Purpose Mesenteric resection in Crohn's disease (CD) is still controversial and under discussion. We performed a meta-analysis to assess recurrence rates and operative-related morbidity based on the extent of mesenteric resection.

Methods A comprehensive literature research was conducted until November 2024 using PubMed (Medline), the Cochrane Central trials register, and Google Scholar databases. Studies before the biological era or with Kono-S anastomosis were excluded. Data from comparative studies with reported patient characteristics and outcome results of extended and limited mesenteric resections were extracted and subsequently entered into a pairwise meta-analysis model. Odds ratios (ORs) for dichotomous variables and standardized mean differences (SMDs) for continuous outcomes with 95% confidence intervals (CIs) were calculated. The risk of bias was rated according to ROBINS-I and Rob2 criteria, respectively.

Results Four non-randomized studies and one randomized trial with a total of 4358 patients (extended mesenteric resection: $n=993$ versus mesenteric preservation: $n=3365$) met eligibility criteria and were included. Extended mesenteric resection was significantly associated with reduced surgical recurrence rates compared to mesenteric preservation (OR = 4.94; 95% CI [2.22–10.97]; $p < 0.001$, $I^2 = 0\%$). In terms of endoscopic recurrence, postoperative morbidity, and hospital stay, no significant differences between both groups were noted within the short follow-up period.

Conclusion Extended mesenteric resection demonstrated a lower surgical recurrence rate in Crohn's disease, while morbidity rates were comparable to the mesenteric sparing approach, whether extended mesenteric excision should be recommended requires further high-quality randomized trials with long-term follow-up data.

Keywords Crohn's disease · Mesenteric resection · Recurrence rate · Complications

Introduction

Over the course of the last three decades, major breakthroughs have been made, unlocking novel therapeutic strategies for patients with Crohn's disease (CD). Despite of this, the majority will have to undergo one or more surgeries over

their lifetime [1, 2]. As a result, this raises the question of the appropriateness of contemporary surgical methods which, more or less, have not evolved at the same pace. Two distinct stages of the surgical approach can be individually investigated and modified in order to pursue a better outcome, with the first one being the resectional and the second one the reconstructive stage. With regard to the latter, the introduction of the Kono-S anastomotic technique offers a potential option to reduce recurrence rates through the exclusion of the mesentery from the anastomosis and thus the prevention of anastomotic distortion [3, 4]. The resectional stage has traditionally been based on the axiomatic approach of "as much as necessary – as little as possible" referring more to the extent of intestinal length excision rather than the mesenteric radicality. The aspect of the excisional extent of the intestinal mesentery is not new. Based on reports that demonstrate the mesentery of the inflamed bowel as a discrete functional entity that has been associated with disease

✉ Dimitrios Prassas
Dimitrios.Prassas@med.uni-duesseldorf.de

¹ Department of Surgery (A), Heinrich-Heine-University, Medical Faculty and University Hospital Duesseldorf, Moorenstr. 5, Bldg. 12.46, 40225 Duesseldorf, Germany

² Department for Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

³ Department of Surgery, Katholisches Klinikum Essen, Philippsstift, Teaching Hospital of Duisburg-Essen University, Huelsmannstr. 17, 45355 Essen, Germany

activity [5], this organ has been targeted as its regulator [6, 7].

With the present work, we sought to meta-analyze all contemporary existing studies comparing limited to extended mesenteric excision of the bowel with regard to its efficiency and safety in patients with CD requiring surgical resection.

Materials and methods

This meta-analysis was conducted in accordance with the current PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and the latest version of the Cochrane Handbook for Systematic Reviews of Interventions, to ensure transparency and adequate study evidence [8, 9].

Literature search

Two authors (S.V. and A.A.) independently performed a comprehensive research for relevant literature in the PubMed (Medline), the Cochrane Central trials register, and Google Scholar databases until November 9, 2024, through screening of article titles and abstracts. No language restriction was applied. The following medical subject headings were combined with the Boolean operators AND or OR: [(mesenteric* resection) AND Crohn's]. After full-text review, the reference lists of all selected and eligible articles were comprehensively checked for further potentially relevant citations. Disagreements were resolved by discussion and consensus or consultation of a third author (D.P.) if necessary.

Inclusion and exclusion criteria

All comparative studies such as randomized controlled trials (RCTs), and prospective or retrospective cohort studies reporting clinical outcomes of extended mesenteric resection as the intervention of interest (i.e. mesofascial separation and vascular mesenteric pedicle division at various levels) versus mesenteric preservation (mesenteric resection in bowel proximity [10], comparator) during segmental bowel resection for Crohn's disease were included. The exclusion criteria were as follows: case/technical reports, editorials or narrative reviews, non-peer-reviewed articles, studies from the pre-biological era, studies comparing Kono-S anastomosis with conventional techniques, and studies that did not report specific outcomes of interest. For data integrity, the reported outcomes of interest in each included study should enable the calculation of odds ratios (ORs) with 95% confidence intervals (CIs). Only studies with adult participants were considered. Discrepancies in study selection were resolved either by consensus or by consultation with an independent third author (D.P.).

Data extraction and outcomes of interest

Two authors (S.V. and A.A.) independently collected all available and relevant data from studies meeting the inclusion criteria. The extracted data contain the following information: (a) study characteristics (authors, year and country of publication, enrollment period, study design and protocol, number of included patients), (b) patients baseline demographics, comorbidities, disease characteristics and medication, (c) surgical technique and intraoperative details, and (d) postoperative short- and long-term outcomes. If the authors were unable to achieve consistent results during data extraction, an independent third reviewer (D.P.) was consulted for advice. The primary endpoint was the rate of surgical recurrence (defined as the need of reoperation for recurrent CD). The secondary outcomes included endoscopic recurrence (defined as Rutgeerts score from i2 to i4 [11], or modified Rutgeerts' score of i2b or higher [12] within 6–12 months after index surgery), duration of surgery, protective ostomy, anastomotic leak, transfusion, surgical site infection (SSI), overall morbidity, major complications (according to Clavien-Dindo and ACS-NSQIP, respectively [13, 14]), mortality, and length of hospital stay.

Quality and certainty assessment

The risk of bias for the included non-randomized studies was assessed using the ROBINS-I criteria as recommended in the Cochrane Handbook for Systematic Reviews of Interventions [15]. This tool categorizes the risk of bias in non-randomized studies from low to critical based on seven potential bias domains. In parallel, the risk of bias of in one randomized study was evaluated using the RoB 2 criteria, which categorizes randomized trials into low to high risk of bias based on signaling questions derived from five potential bias domains [16]. The revised AMSTAR 2 instrument was used to critically appraise this meta-analysis [17]. The level of evidence for the significant outcomes was classified into four categories (high, moderate, low, and very low) according to GRADE (The Grading of Recommendations, Assessment, Development, and Evaluation) [18]. Study quality and certainty judgement was performed independently by two authors (S.V. and A.A.). Disagreements during this step were discussed and resolved by consensus or reassessment by a third author (D.P.).

Statistical analyses

Data of interest was analyzed with pairwise meta-analyses. For each primary and secondary outcome, summary treatment effect estimates with 95% confidence intervals (CIs)

were calculated. For dichotomous endpoints, the odds ratio (OR) was chosen as the effect measure. Standardized mean differences (SMD) were calculated to analyze continuous outcomes. For continuous variables, the available data on medians and IQRs (interquartile range) have been converted into means and standard deviations applying the methods proposed by Luo et al. and Wan et al. [19, 20]. Using the Cochrane Q test (chi-squared test; χ^2) and the measurement of inconsistency (I^2), the degree of heterogeneity among the included studies was interpreted as follows: 0–40% low heterogeneity and may not be important, 30–60% moderate heterogeneity, 50–90% substantial heterogeneity, > 75% considerable heterogeneity [8]. When heterogeneity was low or moderate ($I^2 < 50\%$), summary estimates were calculated using a fixed-effects method. Where appropriate, subgroup analysis was conducted to ensure the robustness of the overall heterogeneity in the results. Leave-one-out analysis investigated the effect of each study on the pooled


outcomes. Statistical significance was defined as p values < 0.05 of pooled data. Statistical analysis was performed using RevMan software (version 5.3; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results

Study and patient characteristics

The initial literature research resulted in 19,166 studies for inclusion. After removing duplicates and non-contributory studies, 28 full-text manuscripts were screened, 23 of which were excluded taking into account the defined inclusion and exclusion criteria. Finally, five eligible studies involving 4550 patients remained that were subsequently included in the qualitative and quantitative meta-analysis [21–25] (Fig. 1 PRISMA Flowchart). In four

Fig. 1 PRISMA flowchart of study identification and selection



non-randomized studies [21–24] and one randomized trial [25], a total of 4358 patients were analyzed (extended mesenteric resection: $n = 993$ versus mesenteric preservation: $n = 3365$). The male to female ratio was 2072:2286. The study enrollment period was from January 2004 to April 2023. Three studies originated from European countries [21, 23, 25], while one study was conducted in Canada [24] and one in China [22], respectively. The study of van der Does de Willeboise et al. [25] was the only included multicenter RCT from the Netherlands with 133 patients. Abdulkarim et al. [24] performed their study as a retrospective ACS database query including 3709 patients. Two studies were conducted as single-center studies [21, 22] and one as a bi-center study [23]. Patients exclusively undergoing ileocolic resection were included in three studies accounting for 12% of all performed procedures [21, 23, 25]. In contrast, two studies included patients with a various extent and location of colectomy (right colectomy 60.6%, transverse colectomy 0.2%, left colectomy 0.8%, total colectomy 0.5%, proctectomy 0.1%, and other non-defined segmental resections 25.9%) [22, 24]. The application of biologicals at index surgery was mentioned in four studies with a total of 136 patients which corresponds to 21% of all patients in these studies [21–23, 25]. Noteworthy, in two studies, follow-up ranged from 30 days to 6 months [24, 25], in contrast to long-term outcome data provided in three other studies [21–23]. A full and detailed study and patient summary is presented in Tables 1 and 2.

Study quality and risk of bias

The overall risk of bias of the four included non-randomized studies was rated from serious to low based on the proposed seven bias domains in the ROBINS-I tool. The risk of bias in the domain of confounding was serious in one study [21], moderate in one study [24] and low in two studies [22, 23]. The risk of bias in the domain selection of study participants was judged as moderate in all studies [21–24]. The risk of bias arising from classification of interventions, deviations from intended interventions, and measurement of outcomes was rated low in all non-randomized studies [21–24]. Two studies were observed to have moderate risk of bias in the domains missing outcomes and selection of reported results [21, 24]. Furthermore, the only randomized study was analyzed as having some risk of bias concerns especially in the categories missing outcome data and selection of the reported results, respectively [25]. The methodological quality of the pooled evidence in this meta-analysis was determined as “high” using the AMSTAR 2 quality assessment tool. The risk of bias evaluation is demonstrated in Fig. 2.

Primary outcome

Surgical recurrence

Surgical recurrence as the primary outcome was reported in three studies with a total of 416 patients [21–23]. Meta-analysis of the pooled data revealed a significantly lower rate of surgical recurrence associated with extended mesenteric resection compared to the control group (OR = 4.94; 95%CI [2.22–10.97]; $p < 0.0001$). The rate of heterogeneity was notably low ($I^2 = 0\%$, χ^2 test: $p = 0.51$) (Fig. 3). The certainty of evidence was judged as high based on GRADE criteria (Table suppl. 1).

Secondary outcomes

Non-significant differences between extended mesenteric resection and mesenteric preservation were observed for all secondary outcomes of interest, especially overall and severe postoperative morbidity was not increased with extended mesenteric resection. The results are presented in Table 3.

Discussion

Extended mesenteric excision is not a novel concept [26], but is increasingly utilized, in conjunction with modern medical treatment regimens and alternative anastomotic approaches, as an efficient amendment to the classic tubular bowel resection. The mesentery-preserving strategy is based on the hypothesis that the biological profile of CD is mostly dependent on gut microbiome and the intestinal barrier. Coffey et al. [27] revitalized the interest towards the mesentery as a distinct anatomic and pathophysiologic entity by underlining its role in metabolism and as mediator of immune response. Increasing evidence shows that structural abnormalities of the mesentery are closely linked to disease progression and recurrence, rendering it a key mediator of inflammatory activity due to interaction between adipocytes, neuropeptides and lymphatic and vascular endothelia, causing remodeling of the involved adipose tissue [28–31]. Again, Coffey et al. [7, 27] were the first to revive this concept and implement it into surgical practice by conducting the first contemporary comparative study of tubular versus extended resections for CD, with more studies following. Here, it should be highlighted that the specimen length was mentioned in only three included studies [21, 23, 25] and two authors provided data on the resection status [22, 25]. In two studies [21, 23], there was a clear trend towards a longer specimen length in the limited mesenteric approach, while in the study by van der Does de Willeboise et al. [25] only the ileal specimen was longer in the mesenteric sparing group. On the other hand, in the study by

Table 1 Study characteristics and protocols

Author	Year	Origin	Recruitment period	Study design	Total sample size	Inclusion criteria	Type of procedure (groups)	Type of access/surgeons involved	Follow-up period (months) mean/SD	Endpoint(s)
Coffey et al. [21]	2018	Ireland	Jan 2004–Apr 2010	Single center, retrospective	64	Ileocolic resection for a Crohn's related ileocolic disease	Group A: conventional ileocolic resection Group B: ileocolic resection with mesenteric excision	Open and MIS/multiple	Group A: 69.9 ± 48.47 Group B: 51.7 ± 20.98	Surgical recurrence
Zhu et al. [22]	2021	China	Jan 2000–Dec 2018	Single-center, prospective	126	Crohn's colitis with colorectal resection	LME: mesenteric sparing colorectal resection EME: mesenteric mobilization and division 1-cm distant from the origin of the major arterial trunks	NA	LME: 45.12 6 ± 25.45 EME: 47.50 ± 623.67	Early postoperative short-term outcome and surgical recurrence
Mineccia et al. [23]	2022	Italy	Jan 2009–Dec 2019	Bi-center, retrospective (Remedy study)	326	Crohn's disease localized to the terminal ileum	Group A: mesenteric resection Group B: mesenteric preservation	Open and MIS/multiple	Median 4.7 ± 3 (years)	90-day complications, endoscopic FU, long-term surgical recurrence
Abdulkarim et al. [24]	2023	Canada	2014–2019	ACS-NSQIP database, retrospective	3709	Patients with CD undergoing segmental colectomy	Extended ME: lymph node harvest ≥ 12 Limited ME: < 12 lymph node	Open and MIS/multiple	30 days	30-day NSQIP major morbidity, abdominal complications, perioperative bleeding
van der Does de Willebois et al. [25]	2024	Netherlands	Feb 2020–Apr 2023	Multicenter, RCT (SPICY trial -NCT 04538638)	139	Aged ≥ 16 and Crohn's disease (L1 or L3 disease)	Extended mesenteric resection (intervention) or conventional mesenteric sparing resection (control)	MIS/multiple	6 months	Endoscopic recurrence 6 months after surgery

CD, Crohn's disease; FU, follow-up; EME, extended mesenteric excision; LME, limited mesenteric excision; MIS, minimally invasive surgery; NA, not available; NSQIP, National Surgical Quality Improvement Program; RCT, randomized controlled trial; SD, standard deviation

Table 2 Patient-and disease characteristics

Author	Groups	No. of patients	Age at surgery (years) mean/SD	Gender (M/F)	Disease duration (months) mean /SD	Biologicals at index surgery	Smoking	Disease classification		Site of surgery
								Age	Location	Phenotype
Coffey et al. [21]	LME	30	37.7 ± 13.67	14/16	75.0 ± 117.42	5	20	A1 < 40 23*	L1 23	Ileocolic resection 30
								A2 ≥ 40 6	L2 2 L3 4 L4 0	B1 16 B2 6 B3 8
Zhu et al. [22]	LME	60	31.15 ± 10.36	47/13	51.19 ± 49.36	4	9	A1 < 40 26 A2 ≥ 40 6	L1 26 L2 0 L3 6 L4 2	Ileocolic resection 34
								A1 ≤ 16 7† A2 17–40 44 A3 > 40 12	L1 0 L2 32 L3 28 L4 1	Right colectomy 26 Transverse colectomy 4 Left colectomy 21 Proctectomy 2 Total colectomy 7
Mineccia et al. [23]	LME	122	40.7 ± 16	70/52	7.7 ± 8.6 (years median)	16	35	A1 ≤ 16 4 A2 17–40 50 A3 > 40 12	L1 0 L2 41 L3 25 L4 4	Right colectomy 32 Transverse colectomy 3 Left colectomy 14 Proctectomy 1 Total colectomy 16
								A1 ≤ 16 15† A2 17–40 68 A3 > 40 39	NA	Ileocolic resection 122
Abdulkarim et al. [24]	LME	3087	42.3 ± 16.76	1408/1679	7.5 ± 8.3 (years median)	32	75	A1 ≤ 16 12 A2 17–40 140 A3 > 40 52	NA	Ileocolic resection 204
								NA	NA	B1 0 B2 67 B3 137
van der Does de Willeboise et al. [25]	LME	66	36.29 ± 18.18	28/38	59.47 ± 85.64	25	25	A1 ≤ 16 8† A2 17–40 40 A3 > 40 18	L1 40 L3 26 B3 22	Right colectomy 2165 Other segmental colectomy 922
								NA	NA	NA
Willeboise et al. [25]	LME	622	41.0 ± 15.78	299/323	58.99 ± 61.36	35	30	A1 ≤ 16 4 A2 17–40 38 A3 > 40 25	NA	Right colectomy 416 Other segmental colectomy 206
								NA	NA	NA
van der Does de Willeboise et al. [25]	LME	66	40.58 ± 23.48	29/38	58.99 ± 61.36	35	30	A1 ≤ 16 4 A2 17–40 38 A3 > 40 25	L1 44 L3 23	Ileocolic resection 66
								NA	NA	NA
Willeboise et al. [25]	LME	67	40.58 ± 23.48	29/38	58.99 ± 61.36	35	30	A1 ≤ 16 4 A2 17–40 38 A3 > 40 25	L1 44 L3 23	Ileocolic resection 67
								NA	NA	NA

EME, extended mesenteric resection; LME, limited mesenteric resection; SD, standard deviation; NA, not available; ME, mesenteric excision

*Vienna Classification

†Montreal Classification




Fig. 2 Risk of bias summary according to **a** ROBINS-I, **b** RoB2

Zhu et al. [22], the CD affected resection margins did not differ significantly between the two groups with limited and extended resection, while van der Does de Willeboise et al. [25] reported a higher inflammatory involvement of the

distal colonic margin in the group with limited resection as opposed to extended mesenteric excision (18% versus 5%, $p=0.023$). Interestingly, recurrence rates do not appear to correlate with margin status and specimen length based on




Fig. 3 Forrest plot for primary outcome extended mesenteric resection versus control: surgical recurrence

Table 3 Non-significant secondary outcomes

Outcomes	No. of included studies	No. of included patients		SMD/OR [95% CI]	P-value	Heterogeneity level	
		Mesenteric preservation	Mesenteric excision			I^2 (%)	P-value
Endoscopic recurrence	2 [23, 25]	187	270	1.07 [0.73–1.56]	0.72	0	0.89
Surgery duration (min)	3 [23–25]	3274	892	−0.04 [−0.12–0.03]	0.26	0	0.48
Protective ostomy	2 [22, 24]	3147	688	1.10 [0.80–1.52]	0.56	0	0.44
Anastomotic leak	3 [22, 24, 25]	2980	721	1.06 [0.35–3.24]	0.91	51	0.13
Transfusion	2 [22, 24]	3147	688	0.86 [0.63–1.18]	0.36	0	0.77
Surgical site infection	2 [22, 24]	3147	688	1.00 [0.77–1.31]	0.99	0	0.60
Overall morbidity	3 [22–24]	3269	892	1.13 [0.94–1.37]	0.21	0	0.71
Major morbidity	3 [23–25]	3274	892	1.01 [0.81–1.26]	0.90	0	0.48
Mortality	4 [22–25]	3334	958	1.96 [0.27–14.52]	0.51	0	0.89
Length of hospital stay (days)	4 [22–25]	3334	958	0.02 [−0.06–0.09]	0.69	28	0.24

CI, confidence interval; OR, odds ratio; SMD, standardized mean difference

the data of the included studies. This in turn is a contrast to a recently published meta-analysis, demonstrating inflammatory margins to be associated with postoperative recurrence after ileocecal resection in CD [32]. At this point, it must be noted that the term radical excision does not always imply the exact same operative technique. Zhu et al. [22] and Mineccia et al. [23] define it as full mesenteric mobilization with division in close proximity to the major arterial trunks, similar to oncologic colorectal resections, whereas Coffey et al. [21] describe his technique as division of the mesentery as close to the mesenteric root as deemed safe. On the other hand, the mesenteric resections in the SPICY study [25] were performed following the lower border of the ileocolic artery, preserving its vascular trunk. The lack of predefined mesenteric borders of the resection is most prominent in the study of Abdulkarim et al. [24], in which lymph node harvest alone was used as a surrogate for radicality. This is the first meta-analysis of studies comparing the above-mentioned procedures. Upon extensive literature research, six comparative contemporary studies and one trial from 1989 [26] were identified. In order to eliminate the potential heterogeneity generated by the synergistic effects of concomitant medications of different classes on treatment response, we opted for exclusion of trials published in the pre-biologic era [33]. This exclusion criterion becomes more important when one considers that in Coffey's study, 44.1% of patients in the mesenteric excision group (recurrence rate 3%) had biologic therapy at index surgery compared to only 16.7% in the non-excision group which is further related to the different time periods of surgery in both groups [34]. The Kono-S anastomosis has been shown to have a positive effect on reducing disease recurrence [35, 36], so we excluded one study comparing the Kono-S, extended mesenteric resection and the combination of Kono-S and extensive mesenteric

resection techniques to ensure homogeneity and comparability [37]. Our meta-analysis demonstrated homogeneous results in support of extended mesenteric resection with regard to clinical recurrence requiring surgery (OR = 4.94; 95% CI [2.22–10.97]; $p < 0.001$, $I^2 = 0\%$). Endoscopic recurrences were reported in just two of the included studies [23, 25]. Despite the higher incidence in the non-excisional subgroup, this effect did not manage to reach statistical significance. One possible explanation of this finding would be the relatively short follow-up period of six months in the SPICY trial [25]. This becomes clear when one considers the recurrence rates of up to 40% in patients with negative initial postoperative surveillance endoscopy, after a median follow-up period of 3.5 years [38]. Furthermore, in light of our results regarding surgical recurrence, the fact that disease progression is linear suggests that endoscopic recurrence could be higher at longer surveillance. Long-time results of the SPICY trial are yet to be published [39]. Another important clue is the different endoscopic scoring system in the two included studies in which endoscopic recurrence was investigated. While Mineccia et al. [23] used the Rutgeerts score for endoscopic recurrence evaluation, in the study of van der Does de Willebois et al. [25], endoscopic recurrence was judged by the modified Rutgeerts classification. An accurate diagnosis and classification of the endoscopic recurrence is of the utmost importance, as it determines the further disease course, the type of medical treatment, and the quality of life [40]. In this context, a recent meta-analysis of 76 studies showed a wide variation in endoscopic recurrence (5–93%) after surgical resection for CD, depending on the endoscopic scoring system used [41]. Ultimately, the identification of high-risk individuals with regard to recurrence and CD-related morbidity is the fundamental aim of postoperative management. The guidelines published

by the American Gastroenterological Association in 2017 have generally served as the guiding beacon for stratifying and accordingly treating patients at risk, and have recently been renewed by the new practice guideline published in 2024 [42]. Studies included in the present meta-analysis demonstrate a rather inhomogeneous pattern with regard to the above matter, reflecting the need for a more standardized algorithmic approach of postoperative medical management. There was no statistically significant difference noted, concerning overall postoperative morbidity within the two study groups. Even after investigating various postoperative complications, still both approaches were found to deliver comparable results. Nevertheless, most of those secondary outcome assumptions derive from pooling of just two studies and should be interpreted cautiously. The presented finding could have a trend-setting impact on the current surgical practice in CD. The latest European Crohn's and Colitis Organization (ECCO) guidelines state that there is insufficient evidence supporting extended mesenteric excision in ileocecal CD [43]. Recent studies have shown that postoperative disease recurrence is significantly lower depending on the type of anastomotic technique and the extent of resection margin involvement [44, 45], indicating that surgical procedures for CD can be further improved and optimized [46].

Our meta-analysis has some limitations. Firstly, the number of studies that could be included was relatively low. Surgical expertise of the operating surgeons was variable and thus a potential source of bias. The heterogeneity of the present meta-analysis with regard to inclusion of non-exclusively ileocecal resections and the use of different operative techniques may influence comparability of the presented results. Postoperative surveillance strategies, medical treatment regimens that change even within the same study period and follow-up time vary significantly. In addition, positive resection margins should be taken into consideration in future comparative trials as a significant confounding factor for disease recurrence, perhaps by excluding selected cases and/or matching between study arms as appropriate. Only one of the included studies was a randomized controlled trial [25]. Long-time results of this trial, as well as preliminary results of other ongoing RCTs are yet to be published [47–49].

Conclusion

Extended mesenteric resection was associated with a reduced incidence of postoperative surgical recurrence of Crohn's disease, without demonstrating any additional morbidity. Due to the lack of high-quality trials, non-standardized operative technique, varying postoperative endoscopic surveillance classification, and heterogeneity of postoperative medical treatment, the results should be interpreted with caution.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00384-025-04845-6>.

Author contributions Study conception and design (D.P. and S.V.), Literature search and study selection (D.P., S.V., and A.A.), Acquisition and extraction of data (S.V. and A.A.), Analysis and interpretation of data (D.P. and S.V.), Statistical analysis (D.P.), Drafting of manuscript (S.V. and D.P.), Critical review and revision of manuscript (W.T.K. and H.K.). All the authors approved the final manuscript version.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability No datasets were generated or analysed during the current study.

Declarations

Ethics approval This article does not contain any studies with human participants or animals performed by any of the authors. For this type of study, no ethical approval was required and obtained.

Informed consent For this type of study informed consent was not required.

Competing interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Lewis RT, Maron DJ (2010) Efficacy and complications of surgery for Crohn's disease. *Gastroenterol Hepatol (N Y)* 6:587–596
2. Chardavoyne R, Flint GW, Pollack S, Wise L (1986) Factors affecting recurrence following resection for Crohn's disease. *Dis Colon Rectum* 29:495–502. <https://doi.org/10.1007/BF02562601>
3. Kono T, Fichera A (2020) Surgical treatment for Crohn's disease: a role of Kono-S anastomosis in the west. *Clin Colon Rectal Surg* 33:335–343. <https://doi.org/10.1055/s-0040-1714236>
4. Cathomas M, Saad B, Taha-Mehlitz S et al (2024) Safety and effectivity of Kono-S anastomosis in Crohn's patients: a systematic review and Meta-analysis. *Langenbecks Arch Surg* 409:227. <https://doi.org/10.1007/s00423-024-03412-x>
5. Desreumaux P, Ernst O, Geboes K et al (1999) Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. *Gastroenterology* 117:73–81. [https://doi.org/10.1016/s0016-5085\(99\)70552-4](https://doi.org/10.1016/s0016-5085(99)70552-4)
6. Coffey JC, O'Leary DP, Kiernan MG, Faul P (2016) The mesentery in Crohn's disease: friend or foe? *Curr Opin Gastroenterol* 32:267–273. <https://doi.org/10.1097/MOG.0000000000000280>

7. Coffey JC, Byrnes KG, Walsh DJ, Cunningham RM (2022) Update on the mesentery: structure, function, and role in disease. *Lancet Gastroenterol Hepatol* 7:96–106. [https://doi.org/10.1016/S2468-1253\(21\)00179-5](https://doi.org/10.1016/S2468-1253(21)00179-5)
8. Cochrane Handbook for Systematic Reviews of Interventions. <https://training.cochrane.org/handbook>. Accessed 10 Nov 2024
9. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *Open Med* 3:e123–130
10. Gionchetti P, Dignass A, Danese S et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. *J Crohns Colitis* 11:135–149. <https://doi.org/10.1093/ecco-jcc/jjw169>
11. Rutgeerts P, Geboes K, Vantrappen G et al (1990) Predictability of the postoperative course of Crohn's disease. *Gastroenterology* 99:956–963. [https://doi.org/10.1016/0016-5085\(90\)90613-6](https://doi.org/10.1016/0016-5085(90)90613-6)
12. Gecke K, Lowenberg M, Bossuyt P et al (2014) Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn's disease using the Rutgeerts score. *Gastroenterology* 146(5):S–227. [https://doi.org/10.1016/S0016-5085\(14\)60802-7](https://doi.org/10.1016/S0016-5085(14)60802-7). (Supplement 1)
13. Hutter MM, Rowell KS, Devaney LA et al (2006) Identification of surgical complications and deaths: an assessment of the traditional surgical morbidity and mortality conference compared with the American College of Surgeons-National Surgical Quality Improvement Program. *J Am Coll Surg* 203:618–624. <https://doi.org/10.1016/j.jamcollsurg.2006.07.010>
14. Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 250:187–196. <https://doi.org/10.1097/SLA.0b013e3181b13ca2>
15. Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 355:i4919. <https://doi.org/10.1136/bmj.i4919>
16. Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 366:14898. <https://doi.org/10.1136/bmj.14898>
17. Shea BJ, Reeves BC, Wells G et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 358:j4008. <https://doi.org/10.1136/bmj.j4008>
18. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 7. Rating the quality of evidence—inconsistency. *J Clin Epidemiol* 64:1294–1302. <https://doi.org/10.1016/j.jclinepi.2011.03.017>
19. Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 27:1785–1805. <https://doi.org/10.1177/0962280216669183>
20. Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 14:135. <https://doi.org/10.1186/1471-2288-14-135>
21. Coffey CJ, Kiernan MG, Sahebally SM et al (2018) Inclusion of the mesentery in ileocolic resection for Crohn's disease is associated with reduced surgical recurrence. *J Crohns Colitis* 12:1139–1150. <https://doi.org/10.1093/ecco-jcc/jjx187>
22. Zhu Y, Qian W, Huang L et al (2021) Role of extended mesenteric excision in postoperative recurrence of Crohn's colitis: a single-center study. *Clin Transl Gastroenterol* 12:e00407. <https://doi.org/10.14309/ctg.0000000000000407>
23. Mineccia M, Maconi G, Daperno M et al (2022) Has the removing of the mesentery during ileo-colic resection an impact on post-operative complications and recurrence in Crohn's disease? Results from the resection of the mesentery study (Remedy). *J Clin Med* 11:1961. <https://doi.org/10.3390/jcm11071961>
24. Abdulkarim S, Salama E, Pang AJ et al (2023) Extended versus limited mesenteric excision for operative Crohn's disease: 30-Day outcomes from the ACS-NSQIP database. *Int J Colorectal Dis* 38:268. <https://doi.org/10.1007/s00384-023-04561-z>
25. van der Does de Willebois EML, Bellato V, Duijvestein M et al (2024) Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial. *Lancet Gastroenterol Hepatol* 9:793–801. [https://doi.org/10.1016/S2468-1253\(24\)00097-9](https://doi.org/10.1016/S2468-1253(24)00097-9)
26. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ (1989) Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. *Digestion* 42:224–232. <https://doi.org/10.1159/000199850>
27. Coffey JC, O'Leary DP (2016) The mesentery: structure, function, and role in disease. *Lancet Gastroenterol Hepatol* 1:238–247. [https://doi.org/10.1016/S2468-1253\(16\)30026-7](https://doi.org/10.1016/S2468-1253(16)30026-7)
28. Meijer LL, Ayez N, van Kessel CS (2023) Crohn's disease: preserve or resect the mesentery? *Br J Surg* 110:1415–1418. <https://doi.org/10.1093/bjs/znad135>
29. Li Y, Ge Y, Gong J et al (2018) Mesenteric lymphatic vessel density is associated with disease behavior and postoperative recurrence in Crohn's disease. *J Gastrointest Surg* 22:2125–2132. <https://doi.org/10.1007/s11605-018-3884-9>
30. Holt DQ, Moore GT, Strauss BJG et al (2017) Visceral adiposity predicts post-operative Crohn's disease recurrence. *Aliment Pharmacol Ther* 45:1255–1264. <https://doi.org/10.1111/apt.14018>
31. Duan M, Coffey JC, Li Y (2024) Mesenteric-based surgery for Crohn's disease: evidence and perspectives. *Surgery* 176:51–59. <https://doi.org/10.1016/j.surg.2024.02.025>
32. Yzet C, Riault C, Brazier F et al (2023) Positive margins and plexitis increase the risk of recurrence after ileocecal resection: a systematic review and meta-analysis. *Dig Liver Dis* 55:1611–1620. <https://doi.org/10.1016/j.dld.2022.12.021>
33. Jain SR, Ow ZGW, Chin YH et al (2021) Quantifying the rate of recurrence of postoperative Crohn's disease with biological therapy. A meta-analysis *J Dig Dis* 22:399–407. <https://doi.org/10.1111/1751-2980.13025>
34. Buskens CJ, Bemelman WA (2018) Inclusion of the mesentery in ileocolic resection for Crohn's disease is associated with reduced surgical recurrence : editorial by Coffey et al. *J Crohns Colitis* 12:1137–1138. <https://doi.org/10.1093/ecco-jcc/jjy115>
35. Nardone OM, Calabrese G, Barberio B et al (2024) Rates of endoscopic recurrence in postoperative Crohn's disease based on anastomotic techniques: a systematic review and meta-analysis. *Inflamm Bowel Dis* 30:1877–1887. <https://doi.org/10.1093/ibd/izad252>
36. Lin W, Lemke M, Ghuman A et al (2024) Effect of Kono-S anastomosis on reducing postoperative recurrence rates in Crohn's disease: a systematic review and meta-analysis. *Tech Coloproctol* 28:127. <https://doi.org/10.1007/s10151-024-02991-7>
37. Holubar SD, Gunter RL, Click BH et al (2022) Mesenteric excision and exclusion for ileocolic Crohn's disease: feasibility and safety of an innovative, combined surgical approach with extended mesenteric excision and Kono-S anastomosis. *Dis Colon Rectum* 65:e5–e13. <https://doi.org/10.1097/DCR.0000000000002287>
38. Pouillon L, Remen T, Amicone C et al (2021) Risk of late postoperative recurrence of Crohn's disease in patients in endoscopic remission after ileocecal resection, over 10 years at multiple centers. *Clin Gastroenterol Hepatol* 19:1218–1225.e4. <https://doi.org/10.1016/j.cgh.2020.05.027>
39. van der Does de Willebois EML, SPICY study group (2022) Mesenteric SPARing versus extensive mesentericCtomY in primary ileocolic resection for ileocaecal Crohn's disease (SPICY): study protocol for randomized controlled trial. *BJS Open* 6:zrab136. <https://doi.org/10.1093/bjsopen/zrab136>

40. Ma C, Gecse KB, Duijvestein M et al (2020) Reliability of endoscopic evaluation of postoperative recurrent Crohn's disease. *Clin Gastroenterol Hepatol* 18:2139–2141.e2. <https://doi.org/10.1016/j.cgh.2019.08.046>
41. van der Does de Willebois EML, Bellato V, Duijvestein M et al (2024) How reliable is endoscopic scoring of postoperative recurrence in Crohn disease?: a systematic review and meta-analysis. *Ann Surg Open* 5:e397. <https://doi.org/10.1097/AS9.0000000000000397>
42. ASGE Ibd Endoscopy Consensus Panel, Shen B, Abreu MT et al (2024) Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. *Gastrointest Endosc* S0016–5107(24):03472–03482. <https://doi.org/10.1016/j.gie.2024.08.034>
43. Adamina M, Minozzi S, Warusavitarne J et al (2024) ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. *J Crohns Colitis* 18:1556–1582. <https://doi.org/10.1093/ecco-jcc/jjae089>
44. Luglio G, Rispo A, Imperatore N et al (2020) Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's disease: the SuPREMe-CD study - a randomized clinical trial. *Ann Surg* 272:210–217. <https://doi.org/10.1097/SLA.00000000000003821>
45. Kelm M, Benatzky C, Buck V et al (2024) Positive resection margins in Crohn's disease are a relevant risk factor for postoperative disease recurrence. *Sci Rep* 14:10823. <https://doi.org/10.1038/s41598-024-61697-w>
46. Kelm M, Flemming S (2025) Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease. *Lancet Gastroenterol Hepatol* 10:15–16. [https://doi.org/10.1016/S2468-1253\(24\)00343-1](https://doi.org/10.1016/S2468-1253(24)00343-1)
47. NCT03172143 (2018) Mesenteric sparing for the prevention of recurrent Crohn's disease. <https://clinicaltrials.gov/show/NCT03172143>. <https://doi.org/10.1002/central/CN-01594650>
48. NCT04578392 (2020) MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's Disease (SPARES). <https://clinicaltrials.gov/show/NCT04578392>. <https://doi.org/10.1002/central/CN-02181819>
49. Li Y, Mohan H, Lan N et al (2020) Mesenteric excision surgery or conservative limited resection in Crohn's disease: study protocol for an international, multicenter, randomized controlled trial. *Trials* 21:210. <https://doi.org/10.1186/s13063-020-4105-x>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.